Literature DB >> 18475525

The temporal relationship between the neural and vascular actions of kallidin within the nose.

K Rajakulasingam1, L C Lau, R Polosa, M K Church, S T Holgate, P H Howarth.   

Abstract

The time course of effect of the B(2)-receptor agonist kallidin (K) on induced changes of nasal airflow, rhinorrhoea, nasal pain, sneezing and nasal microvascular leakage has been examined and compared with its B(2) metabolite agonist bradykinin (B) and the B(1)-agonist [des-arg(9)]-bradykinin (D). When administered as a single dose K and B induced an immediate sensation of pain, rhinorrhoea, elevations in lavage albumin and protein levels and a sustained increase in nasal airways resistance (NAR) for 5-40 min post-challenge. [des-arg(9)]-Bradykinin and vehicle placebo (V) were without effect on any of these indices. These studies identify the action of K and B within the nose and differentiate the neural and vascular effects of these kinins in addition to suggesting the potential that nasal blockage and nasal microvascular leakage represent alterations in differing vascular compartments. These findings have implications for the understanding and therapeutic manipulation of rhinitis.

Entities:  

Year:  1993        PMID: 18475525      PMCID: PMC2365406          DOI: 10.1155/S0962935193000298

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  24 in total

1.  AN IN VIVO ESTIMATION OF THE POTENCIES AND HALF-LIVES OF SYNTHETIC BRADYKININ AND KALLIDIN.

Authors:  D A MCCARTHY; D E POTTER; E D NICOLAIDES
Journal:  J Pharmacol Exp Ther       Date:  1965-04       Impact factor: 4.030

2.  Pharmacology of nasal provocation with bradykinin: studies of tachyphylaxis, cyclooxygenase inhibition, alpha-adrenergic stimulation, and receptor subtype.

Authors:  L Churchill; J A Pongracic; C J Reynolds; R M Naclerio; D Proud
Journal:  Int Arch Allergy Appl Immunol       Date:  1991

3.  Inflammatory mediators in late antigen-induced rhinitis.

Authors:  R M Naclerio; D Proud; A G Togias; N F Adkinson; D A Meyers; A Kagey-Sobotka; M Plaut; P S Norman; L M Lichtenstein
Journal:  N Engl J Med       Date:  1985-07-11       Impact factor: 91.245

4.  Comparative airway response to inhaled bradykinin, kallidin, and [des-Arg9]bradykinin in normal and asthmatic subjects.

Authors:  R Polosa; S T Holgate
Journal:  Am Rev Respir Dis       Date:  1990-12

5.  Bradykinin and respiratory mucous membranes. Analysis of bradykinin binding site distribution and secretory responses in vitro and in vivo.

Authors:  J N Baraniuk; J D Lundgren; H Mizoguchi; D Peden; A Gawin; M Merida; J H Shelhamer; M A Kaliner
Journal:  Am Rev Respir Dis       Date:  1990-03

6.  Albumin, bradykinins, and eosinophil cationic protein on the nasal mucosal surface in patients with hay fever during natural allergen exposure.

Authors:  C Svensson; M Andersson; C G Persson; P Venge; U Alkner; U Pipkorn
Journal:  J Allergy Clin Immunol       Date:  1990-05       Impact factor: 10.793

7.  Capsaicin and nicotine-sensitive afferent neurones and nasal secretion in healthy human volunteers and in patients with vasomotor rhinitis.

Authors:  P Stjärne; L Lundblad; J M Lundberg; A Anggård
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

8.  Comparative nasal effects of bradykinin, kallidin and [Des-Arg9]-bradykinin in atopic rhinitic and normal volunteers.

Authors:  K Rajakulasingam; R Polosa; S T Holgate; P H Howarth
Journal:  J Physiol       Date:  1991-06       Impact factor: 5.182

9.  Kinin metabolism in human nasal secretions during experimentally induced allergic rhinitis.

Authors:  D Proud; C R Baumgarten; R M Naclerio; P E Ward
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

10.  Kallidin applied to the human nasal mucosa produces algesic response not blocked by capsaicin desensitization.

Authors:  P Geppetti; B M Fusco; M Alessandri; M Tramontana; C A Maggi; G Drapeau; M Fanciullacci; D Regoli
Journal:  Regul Pept       Date:  1991-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.